2025
Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss
Fu W, Chen M, Wang K, Chen Y, Cui Y, Xie Y, Lei Z, Hu W, Sun G, Huang G, He C, Fretz J, Hettinghouse A, Liu R, Cai X, Zhang M, Chen Y, Jiang N, He M, Wiznia D, Xu H, Chen Z, Chen L, Tang K, Zhou H, Liu C. Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. Cell Research 2025, 35: 23-44. PMID: 39743632, PMCID: PMC11701132, DOI: 10.1038/s41422-024-01016-0.Peer-Reviewed Original ResearchConceptsGC-induced osteoporosisBone lossInflammatory arthritisAdverse effects of dexamethasoneGlucocorticoid-induced bone lossHigh-dose dexamethasoneEffect of dexamethasoneFDA-approved drug librarySynthetic GCTreat inflammatory arthritisImmunosuppressive drugsPrescribed anti-inflammatoryGC receptorCombinatorial administrationSide effectsLow affinityGlucocorticoidOsteoporosisDexamethasoneReceptorsAdverse effectsBinding receptorsAnti-inflammatoryDrug libraryTau deficiency
2024
Chikungunya Arthritis Treatment with Methotrexate and Dexamethasone: A Randomized, Double-blind, Placebo-controlled Trial
Amaral J, Lucena G, Schoen R. Chikungunya Arthritis Treatment with Methotrexate and Dexamethasone: A Randomized, Double-blind, Placebo-controlled Trial. Current Rheumatology Reviews 2024, 20: 337-346. PMID: 38173199, DOI: 10.2174/0115733971278715231208114037.Peer-Reviewed Original ResearchChronic chikungunya arthritisChikungunya arthritisDouble-blindJoint countPlacebo-controlled clinical trialPain visual analog scalePlacebo-controlled trialChikungunya feverPatient global assessmentVisual analog scaleAffected individualsSwollen joint countTender joint countChikungunya virus infectionDAS28-ESRDexamethasone groupSD ageAnalog scaleBiphasic diseaseTreatment responseClinical trialsAcute phaseDexamethasoneVirus infectionGlobal assessment
2023
Addition of dexamethasone to prolong peripheral nerve blocks: a ChatGPT-created narrative review
Wu C, Cho B, Gabriel R, Hurley R, Liu J, Mariano E, Mathur V, Memtsoudis S, Grant M. Addition of dexamethasone to prolong peripheral nerve blocks: a ChatGPT-created narrative review. Regional Anesthesia & Pain Medicine 2023, 49: 777-781. PMID: 37295794, DOI: 10.1136/rapm-2023-104646.Peer-Reviewed Original ResearchPeripheral nerve blocksNerve blockGenerative Pre-trained TransformerAddition of dexamethasonePre-trained transformersPain medicineArtificial intelligence chatbotsRegional anesthesiaIntelligent chatbotHuman expertsChatGPTNarrative reviewDexamethasoneSearch methodologyLack of noveltyLay audiencesReview articleSubspecialtyAudienceCausal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia
Blette B, Granholm A, Li F, Shankar-Hari M, Lange T, Munch M, Møller M, Perner A, Harhay M. Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. Scientific Reports 2023, 13: 6570. PMID: 37085591, PMCID: PMC10120498, DOI: 10.1038/s41598-023-33425-3.Peer-Reviewed Original ResearchConceptsCritical COVID-19Better long-term outcomesCOVID-19Entire trial populationStandardized dosing protocolsMultiple patient characteristicsDose of dexamethasoneLong-term outcomesIL-6 inhibitorsDexamethasone doseSevere hypoxemiaMost patientsPatient characteristicsRespiratory supportDiabetes mellitusClinical outcomesDosing protocolTrial populationTreatment effect heterogeneityPatient featuresPatientsAdditional studiesDexamethasoneDoseMore evidenceComplete Tolerogenic Adjuvant Stimulates Regulatory T Cell Response to Immunization.
Zheng G, Geng Y, Yan Z, Shin S, Joshi K, Panicker A, Shankar A, Elangovan R, Koehler J, Gnanasekar V, Gilles J, Munirathinam G, Chen A. Complete Tolerogenic Adjuvant Stimulates Regulatory T Cell Response to Immunization. The Journal Of Immunology 2023, 210: 609-617. PMID: 36602931, PMCID: PMC9998350, DOI: 10.4049/jimmunol.2200463.Peer-Reviewed Original Research
2022
A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Gonsalves W, Neparidze N, Allred J, Kumar S, Reid J, Shapiro G, Costello B, Piekarz R, Baz R, Devarakonda S. A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood 2022, 140: 7315-7316. DOI: 10.1182/blood-2022-164966.Peer-Reviewed Original ResearchPersistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia
Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, Winick NJ, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. Journal Of The National Cancer Institute 2022, 114: 1167-1175. PMID: 35552709, PMCID: PMC9360458, DOI: 10.1093/jnci/djac095.Peer-Reviewed Original ResearchReduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study
Stukas S, Goshua G, Kinkade A, Grey R, Mah G, Biggs CM, Jamal S, Thiara S, Lau TTY, Piszczek J, Partovi N, Sweet DD, Lee AYY, Wellington CL, Sekhon MS, Chen LYC. Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. The Lancet Regional Health - Americas 2022, 11: 100228. PMID: 35345649, PMCID: PMC8941850, DOI: 10.1016/j.lana.2022.100228.Peer-Reviewed Original ResearchDoses of tocilizumabCohort studyClinical outcomesIll patientsIll COVID-19 patientsCOVID-19Interleukin-6 inhibitorsSevere COVID-19Weight-based dosingCOVID-19 patientsDrug shortagesNet monetary benefitMedian CRPControl cohortTocilizumabPatientsAssumed willingnessDexamethasoneComparable reductionMortalityPhysiological responsesSignificant differencesOnly groupDoseDoses
2021
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Patel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & Lymphoma 2021, 62: 2777-2784. PMID: 34151696, DOI: 10.1080/10428194.2021.1933477.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioRefractory multiple myelomaMultiple myelomaWeekly selinexorR Multiple MyelomaProgression-free survivalUS payer perspectiveCost-effectiveness ratioWeekly bortezomibTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessBortezomibIncremental costMyelomaDexamethasoneSelinexorQALYVDPatients
2018
Dexamethasone-Related Perineal Burning in the Prehospital Setting: A Case Series
Dylla L, Acquisto N, Manzo F, Cushman J. Dexamethasone-Related Perineal Burning in the Prehospital Setting: A Case Series. Prehospital Emergency Care 2018, 22: 655-658. PMID: 29485338, DOI: 10.1080/10903127.2018.1440039.Peer-Reviewed Original Research
2016
Anti-inflammatory, antioxidant and anti-Mycobacterium tuberculosis activity of viridiflorol: The major constituent of Allophylus edulis (A. St.-Hil., A. Juss. & Cambess.) Radlk.
Trevizan L, do Nascimento K, Santos J, Kassuya C, Cardoso C, do Carmo Vieira M, Moreira F, Croda J, Formagio A. Anti-inflammatory, antioxidant and anti-Mycobacterium tuberculosis activity of viridiflorol: The major constituent of Allophylus edulis (A. St.-Hil., A. Juss. & Cambess.) Radlk. Journal Of Ethnopharmacology 2016, 192: 510-515. PMID: 27612433, DOI: 10.1016/j.jep.2016.08.053.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Inflammatory AgentsAntioxidantsAntitubercular AgentsBenzothiazolesBiphenyl CompoundsCarrageenanChemotaxis, LeukocyteDexamethasoneDisease Models, AnimalDose-Response Relationship, DrugEdemaFemaleGas Chromatography-Mass SpectrometryMaleMiceMycobacterium tuberculosisOils, VolatilePhytotherapyPicratesPlant ExtractsPlant LeavesPlant OilsPlants, MedicinalPleurisySapindaceaeSulfonic AcidsTerpenesTime FactorsConceptsNatural anti-inflammatory agentAnti-inflammatory agentsSubcutaneous injectionOral administrationAnti-Mycobacterium tuberculosis activityAnti-mycobacterial activityAntioxidant activityTotal leucocytesEOAETuberculosis activityMycobacterium tuberculosisGas chromatography-mass spectrometrySignificant inhibitionMiceTraditional medicineEdemaPleurisyPositive controlReference standardDexamethasoneCarrageenanAdministrationModerate antioxidant activityInjectionMajor constituents
2015
Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report.
van Dams R, Park HS, Alomari AK, Ricciardi AS, Rao H, McNamara J, DiLuna ML, Bindra RS. Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report. Journal Of Neurosurgery Pediatrics 2015, 17: 434-8. PMID: 26636250, DOI: 10.3171/2015.8.peds15313.Peer-Reviewed Original ResearchConceptsPartial brain radiation therapyRadiation therapyCase reportSarcoma brain metastasesEvidence of diseaseGross tumor resectionGross total resectionBrain metastasesInflammatory changesIntracranial metastasesSarcoma metastasisTumor resectionMetastasisTherapyResectionPatientsLimited marginReasonable approachReportDexamethasoneDiseaseGyBrainMonths
2014
Loss of the Endothelial Glucocorticoid Receptor Prevents the Therapeutic Protection Afforded by Dexamethasone after LPS
Goodwin JE, Feng Y, Velazquez H, Zhou H, Sessa WC. Loss of the Endothelial Glucocorticoid Receptor Prevents the Therapeutic Protection Afforded by Dexamethasone after LPS. PLOS ONE 2014, 9: e108126. PMID: 25299055, PMCID: PMC4191990, DOI: 10.1371/journal.pone.0108126.Peer-Reviewed Original ResearchConceptsKO miceLow-dose LPSSepsis-like syndromeAnti-inflammatory therapyInflammatory cytokines TNFKO mice showRegulation of NFNF-κB activationNitric oxide releaseTherapeutic protectionIL-6INOS productionCytokines TNFReceptor preventsIdentical doseControl animalsMice showGlucocorticoid receptorOxide releaseDexamethasoneLPSMiceProlonged activationActivationSepsis
2013
Ultrasound-Enhanced Delivery of Antibiotics and Anti-Inflammatory Drugs Into the Eye
Nabili M, Patel H, Mahesh SP, Liu J, Geist C, Zderic V. Ultrasound-Enhanced Delivery of Antibiotics and Anti-Inflammatory Drugs Into the Eye. Ultrasound In Medicine & Biology 2013, 39: 638-646. PMID: 23415283, PMCID: PMC3770302, DOI: 10.1016/j.ultrasmedbio.2012.11.010.Peer-Reviewed Original ResearchConceptsOphthalmic drugsLong-term survival studiesSodium fluoresceinAnti-inflammatory drugsTreatment parameter combinationUltrasound-enhanced deliveryTopical administrationHistologic analysisSurvival studiesCorneaCorneal permeabilityDexamethasoneEpithelial layerTherapeutic drugsRabbit corneaStatistical significanceDrug dexamethasoneDrugsTobramycinUltrasoundEyesDeliveryFuture investigationsAdministrationDrug delivery
2011
Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study.
Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Grady T, Klein C, Mehta P, Hayes T, Roodman G, Lichtenstein A. Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. Journal Of Clinical Oncology 2011, 29: 8074-8074. DOI: 10.1200/jco.2011.29.15_suppl.8074.Peer-Reviewed Original Research
2010
Intravenous dexamethasone followed by oral prednisolone versus oral prednisolone in the treatment of childhood Henoch–Schönlein purpura
Shin J, Lee S, Lee J, Kim K. Intravenous dexamethasone followed by oral prednisolone versus oral prednisolone in the treatment of childhood Henoch–Schönlein purpura. Rheumatology International 2010, 31: 1429-1432. PMID: 20464400, DOI: 10.1007/s00296-010-1507-1.Peer-Reviewed Original ResearchConceptsHenoch-Schonlein purpuraOral prednisoloneAbdominal painIntravenous dexamethasonePL groupDiagnosis of Henoch-Schonlein purpuraResolution of abdominal painHSP childrenIntravenous corticosteroid therapySevere abdominal painDevelopment of nephritisFrequent abdominal painDuration of fastingEffective therapeutic strategyPersistent nephritisCorticosteroid therapyPalpable purpuraFollow-upPrednisolonePainTherapeutic strategiesPatientsPurpuraDexamethasoneSevere symptoms
2009
Prospective Evaluation of Fetuses With Autoimmune-Associated Congenital Heart Block Followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study
Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP. Prospective Evaluation of Fetuses With Autoimmune-Associated Congenital Heart Block Followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. The American Journal Of Cardiology 2009, 103: 1102-1106. PMID: 19361597, PMCID: PMC2730772, DOI: 10.1016/j.amjcard.2008.12.027.Peer-Reviewed Original ResearchConceptsThird-degree blockSecond-degree blockCongenital heart blockFirst-degree blockDEX groupHeart blockAutoimmune-Associated Congenital Heart BlockEfficacy of dexamethasoneSteroid side effectsNormal sinus rhythmMedian ventricular ratesCardiac dysfunctionGestational ageVentricular rateNonrandomized studyProspective evaluationSinus rhythmGrowth restrictionPR intervalPacemaker useRare caseTherapeutic benefitSide effectsBirth ageDexamethasone
2006
Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects
Feldman B, Streeper R, Farese R, Yamamoto K. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 15675-15680. PMID: 17030820, PMCID: PMC1592529, DOI: 10.1073/pnas.0607501103.Peer-Reviewed Original ResearchConceptsInsulin sensitivityFavorable metabolic effectsResistant to diet-induced obesityDiet-induced obesityExpression of myostatinTGF-beta family membersStages of adipogenesisSystemic insulin sensitivityTreat metabolic diseasesTransgenic miceTGF-betaMetabolic effectsExpression markersDexamethasoneMetabolic diseasesMyostatinAdipocytesImmature adipocytesMiceCell culturesAdipogenesisDifferentiation conditions
2004
Effects of glucocorticoids on declarative memory function in major depression
Bremner J, Vythilingam M, Vermetten E, Anderson G, Newcomer J, Charney D. Effects of glucocorticoids on declarative memory function in major depression. Biological Psychiatry 2004, 55: 811-815. PMID: 15050862, DOI: 10.1016/j.biopsych.2003.10.020.Peer-Reviewed Original ResearchConceptsMajor depressive disorderDeclarative memory functionVerbal declarative memory functionDay 3Major depressionMemory functionParagraph recallUnipolar major depressive disorderSubset of patientsEffects of glucocorticoidsHealthy human subjectsDepressive disorderTransient impairmentHealthy subjectsRandomized fashionDeclarative memoryGlucocorticoid receptorBrain regionsExogenous cortisolGlucocorticoidsPlaceboDexamethasonePatientsBaselineDepression
2003
Glucocorticoid Enhances Transforming Growth Factor-β Effects on Extracellular Matrix Protein Expression in Human Placental Mesenchymal Cells1
Lee MJ, Ma Y, LaChapelle L, Kadner SS, Guller S. Glucocorticoid Enhances Transforming Growth Factor-β Effects on Extracellular Matrix Protein Expression in Human Placental Mesenchymal Cells1. Biology Of Reproduction 2003, 70: 1246-1252. PMID: 14681196, DOI: 10.1095/biolreprod.103.021956.Peer-Reviewed Original ResearchConceptsPlacental mesenchymal cellsIntrauterine growth restrictionFFN levelsProtein expressionCol IV expressionInteraction of glucocorticoidsDose-dependent mannerHuman term placentaFibronectin protein levelsExtracellular matrix protein expressionUncomplicated pregnanciesPolymerase chain reaction analysisReal-time polymerase chain reaction analysisGrowth restrictionDEX treatmentChain reaction analysisECM proteinsPlacental villiTerm placentaECM protein expressionCol IIIPlacental architectureMatrix protein expressionDexamethasoneGlucocorticoids
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply